China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial report, showcasing robust growth and providing updates on recent product highlights and corporate developments.
Revenue Growth and Product Performance
During Q3, Zai Lab reported product net revenues of USD 101.8 million, a 46% year-on-year (YOY) increase at constant exchange rates compared to USD 69.2 million in the same period last year. This growth was driven by strong sales of Vygart (efgartigimod alfa), Zejula (niraparib), and Nuzyra (omadacycline). Vygart generated USD 27.3 million in sales, benefiting from its market launch in September 2023 and inclusion in the National Reimbursement Drug List (NRDL) for generalized myasthenia gravis (gMG) on January 1, 2024. Zejula sales reached USD 48.2 million, marking a 16% YOY increase. Nuzyra sales amounted to USD 10 million, up 82% YOY, bolstered by its inclusion in the NRDL for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in Q1 2023 and Q1 2024, respectively.
Pipeline Progress and Future Outlook
KarXT (xanomeline and trospium chloride), a novel combination therapy for schizophrenia, yielded positive results in a China bridging study, with market filing anticipated in early 2025. Additionally, the global Phase I study for ZL-1310, a DLL3-targeted antibody drug conjugate (ADC), demonstrated its best-in-class potential in extensive-stage small cell lung cancer. Zai Lab is on track to commercialize three products by the end of 2024 and plans to submit up to four marketing filings within the next six months.-Fineline Info & Tech
Leave a Reply